Clinical Trials on TTR-mediated Amyloidosis

Total 780 results

Alnylam Pharmaceuticals

Completed

A Study of the Safety, Tolerability and Pharmacokinetics of ALN-TTR02 in Japanese Healthy Volunteers

Transthyretin (TTR)-Mediated Amyloidosis

United Kingdom
Alnylam Pharmaceuticals

Completed

Safety and Tolerability of Patisiran (ALN-TTR02) in Transthyretin (TTR) Amyloidosis

TTR-mediated Amyloidosis

Portugal, Spain, Sweden, Brazil, United States, France, Germany
Alnylam Pharmaceuticals

Completed

A Phase 1, Single- and Multi-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-TTRSC (Revusiran) in Healthy Volunteers

TTR-mediated Amyloidosis

United Kingdom
Alnylam Pharmaceuticals

Completed

Trial to Evaluate Safety, Tolerability, and Parmacokinetics of ALN-TTR02 in Healthy Volunteer Subjects

TTR-mediated Amyloidosis

United Kingdom
Alnylam Pharmaceuticals

Completed

Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac Amyloidosis

TTR-mediated Amyloidosis

United States, United Kingdom
Alnylam Pharmaceuticals

Completed

The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)

TTR-mediated Amyloidosis

Portugal, Sweden, Brazil, United States, France, Spain, Germany
Alnylam Pharmaceuticals

Completed

A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis

TTR-mediated Amyloidosis

United States, Canada, United Kingdom
Alnylam Pharmaceuticals

Completed

Trial to Evaluate Safety and Tolerability of ALN-TTR01 in Transthyretin (TTR) Amyloidosis

Transthyretin Mediated Amyloidosis (ATTR)

United Kingdom, France, Portugal, Sweden
Alnylam Pharmaceuticals

Completed

The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Whose Disease Has Continued to Worsen Following Liver Transplant

ATTR Amyloidosis | Transthyretin (TTR)-Mediated Amyloidosis | Familial Amyloidotic Polyneuropathy (FAP) | Familial Amyloid Neuropathies

France, Germany, Portugal, United Kingdom, Sweden, Spain
Alnylam Pharmaceuticals

Completed

A Safety and Tolerability Study of an Investigational Drug, ALN-TTRSC02, in Healthy Subjects

Transthyretin-mediated Amyloidosis (ATTR Amyloidosis)

United Kingdom
Alnylam Pharmaceuticals

Recruiting

ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis) (ConTTRibute)

Transthyretin-Mediated Amyloidosis | ATTR Amyloidosis

Israel, Italy, Netherlands, Spain, United States, France, Denmark, Germany, Portugal, Brazil, Taiwan
Alnylam Pharmaceuticals

No longer available

Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis With Cardiomyopathy

Transthyretin-mediated Amyloidosis With Cardiomyopathy | ATTR Amyloidosis With Cardiomyopathy

United States
Mayo Clinic

Completed

Long-term Monitoring of Patients With Cardiac Amyloidosis With Implantable Event Monitors

TTR Cardiac Amyloidosis

United States
Alnylam Pharmaceuticals

Completed

ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)

Amyloid Neuropathies | Amyloid Neuropathies, Familial | Amyloidosis, Hereditary | Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC) | Amyloidosis, Hereditary, Transthyretin-Related | Familial Transthyretin Cardiac Amyloidosis

United States, France, Italy, Spain, Canada, Germany, Belgium, Sweden, United Kingdom
IRCCS Policlinico S. Matteo

Completed

A Study of Doxycycline and Tauroursodeoxycholic Acid (Doxy/TUDCA) Plus Standard Supportive Therapy Versus Standard Supportive Therapy Alone in Cardiac Amyloidosis Caused by Transthyretin

TTR Cardiac Amyloidosis

Italy
Alnylam Pharmaceuticals

No longer available

Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)

Amyloid Neuropathies | Amyloid Neuropathies, Familial | TTR-mediated Amyloidosis | Amyloidosis, Hereditary | Amyloidosis, Hereditary, Transthyretin-Related | Familial Amyloid Polyneuropathies
Alnylam Pharmaceuticals

Completed

APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis

Amyloid Neuropathies | Amyloid Neuropathies, Familial | TTR-mediated Amyloidosis | Amyloidosis, Hereditary | Amyloidosis, Hereditary, Transthyretin-Related | Familial Amyloid Polyneuropathies

United States, Canada, Argentina, Australia, Bulgaria, Cyprus, Italy, Japan, Malaysia, Mexico, Netherlands, Portugal, Spain, Sweden, Germany, France, Brazil, Turkey, Korea, Republic of, Taiwan, United Kingdom
Ionis Pharmaceuticals, Inc.
AstraZeneca

Recruiting

An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

United States, Austria, Belgium, Canada, France, Germany, Israel, Italy, Portugal, Spain, Sweden, United Kingdom, Australia, Greece
Ionis Pharmaceuticals, Inc.

Active, not recruiting

CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

United States, Australia, Spain, Canada, Germany, Japan, Italy, Israel, Argentina, France, Portugal, Austria, Brazil, Greece, United Kingdom, Czechia, Sweden, Belgium, Denmark, Poland, Puerto Rico
Alnylam Pharmaceuticals

Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALN-TTRSC04 in Healthy Subjects

Transthyretin-Mediated Amyloidosis

United Kingdom
Kaplan Medical Center

Unknown

Radioisotope Scintigraphy to Establish Incidence of Cardiac Amyloidosis Among Patients With Otherwise Unexplained Cardiac Disease

Cardiac TTR Amyloidosis
IRCCS Policlinico S. Matteo

Recruiting

The Italian Transthyretin Amyloidosis Web-Network (ITA-WebNet)

ATTR Amyloidosis

Italy
Pfizer

Completed

Burden of Disease Study In Patients With Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP) orTransthyretin Cardiomyopathy (TTR-CM) And Caregivers

Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP) | Transthyretin Cardiomyopathy (TTR-CM) | Familial Amyloid Cardiomyopathy | Senile Systemic Amyloidosis (SSA)
Austin Neuromuscular Center
Alnylam Pharmaceuticals

Recruiting

Spectrum of Peripheral and Autonomic Neuropathies in Patients With aTTRwt Amyloidosis and Response to Patisiran Therapy

Polyneuropathies | Transthyretin Amyloidosis | Wild-Type Transthyretin-Related (ATTR)Amyloidosis | Wild-Type Transthyretin Cardiac Amyloidosis | Wild Type ATTR Amyloidosis

United States
Prothena Biosciences Limited

Terminated

A Study of PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis

Amyloidogenic Transthyretin (ATTR) Amyloidosis

United States, Spain, Sweden, Portugal
Steen Hvitfeldt Poulsen

Recruiting

Prevalence of wtATTR-CM After Carpal Tunnel Release Surgery (CACTuS2)

Transthyretin Amyloidosis | Transthyretin Cardiac Amyloidosis | Wild-Type Transthyretin-Related (ATTR)Amyloidosis

Denmark
Paolo Milani

Recruiting

NatiOnal Referral cenTEr Study of Transthyretin Amyloid Cardiomyopathy(ATTR) Patients on Tafamidis (NOTE-ATTR)

Amyloidosis | Amyloidosis Cardiac | ATTR Amyloidosis Wild Type

Italy
Akcea Therapeutics

Recruiting

TEGSEDI Pregnancy Surveillance Program

Pregnancy | Hereditary Transthyretin-mediated Amyloidosis With Polyneropathy

United States
AstraZeneca

Recruiting

OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis (OverTTuRe)

ATTR Amyloidosis

United Kingdom, United States, Denmark, Japan
Pfizer

Completed

Safety And Efficacy Evaluation Of Fx-1006a In Patients With V122i Or Wild-Type Transthyretin (TTR) Amyloid Cardiomyopathy

ATTR-CM | TTR-CM

United States
University of Edinburgh
British Heart Foundation; Netherlands Heart Foundation; Deutsches Zentrum für...

Recruiting

Quantitative-imaging in Cardiac Transthyretin Amyloidosis (I-CARE)

ATTR-CM

Netherlands
Pfizer

Recruiting

Vyndaqel Capsules Special Investigation (ATTR-CM)

Transthyretin (TTR) Amyloid Cardiomyopathy

Japan
Life Molecular Imaging GmbH
pharmtrace klinische Entwicklung GmbH

Recruiting

Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis (CArdiag)

AL Amyloidosis | Cardiac Amyloidosis | ATTR Amyloidosis

United States, Spain, Germany, United Kingdom
Medical University of Graz
Medical University Innsbruck

Recruiting

Association Between Lifetime Physical Activity and Exercise and the Development of Wild-type Transthyretin Amyloid Cardiomyopathy

Amyloid Cardiomyopathy | Wild Type ATTR Amyloidosis

Austria
Thibaud Damy

Completed

Prevalence of Transthyretin Amyloidosis in Hypertrophic Cardiomyopathy (Amylo)

Cardiac Amyloidosis | Hypertrophic Cardiomyopathy (HCM) | Amyloidosis in Transthyretin (TTR)

France
Alnylam Pharmaceuticals

Recruiting

Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program

Polyneuropathy | Hereditary Transthyretin-mediated (hATTR) Amyloidosis

Netherlands, Spain, United States, Germany, France, Italy, Portugal
Steen Hvitfeldt Poulsen

Recruiting

Haemodynamic Effects of Dobutamine in Patients With Wild-type Transthyretin Amyloid Cardiomyopathy (ATTRwt) (DobATTR)

ATTR Amyloidosis Wild Type

Denmark
Pfizer

Completed

Safety And Efficacy Evaluation Of Fx-1006A In Subjects With Transthyretin Amyloidosis

ATTR-PN

United States, Germany, Argentina, Brazil, France, Italy, Portugal, Sweden
Ionis Pharmaceuticals, Inc.
AstraZeneca

Active, not recruiting

The CARDIO-TTRansform Scintigraphy Sub-study

Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

United States, Spain
Alnylam Pharmaceuticals

Completed

A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of ATTRv Amyloidosis With a V122I or T60A Mutation

Polyneuropathy | Hereditary Transthyretin-mediated (ATTRv) Amyloidosis

United States
Midwest Heart & Vascular Specialists

Recruiting

Amyloidosis Incidence in High-Risk Cardiac Device Patients

AL Amyloidosis | Amyloid | Cardiac Amyloidosis | Amyloidosis Cardiac | Systemic Amyloidosis | ATTR Amyloidosis Wild Type | Infiltrative Cardiomyopathy, Amyloid

United States
Ionis Pharmaceuticals, Inc.
AstraZeneca

Active, not recruiting

CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-study

Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

United States, United Kingdom, Italy, Spain
Columbia University
National Institute on Aging (NIA)

Recruiting

Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis

Lumbar Spinal Stenosis | Cardiomyopathy, Hypertrophic | Cardiac Amyloidosis | ATTR Amyloidosis Wild Type | ATTR Gene Mutation | ATTRV122I Amyloidosis

United States
University of Texas Southwestern Medical Center
National Heart, Lung, and Blood Institute (NHLBI); Columbia University; The Cleveland... and other collaborators

Recruiting

Subclinical Transthyretin Cardiac Amyloidosis in V122I TTR Carriers

Amyloidosis, Familial | Amyloidosis, Hereditary | Amyloidosis Cardiac | Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy | Transthyretin Gene Mutation

United States
CENTOGENE GmbH Rostock
Alnylam Pharmaceuticals

Recruiting

TRAMmoniTTR Study Genetic Screening of an At-risk Population for hATTR and Monitoring of TTR Positive Subjects (TRAMmoniTTR)

Cardiomyopathies | Polyneuropathies | Transthyretin Amyloidosis | Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy | Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy

Germany, Austria, Switzerland
Alnylam Pharmaceuticals

Active, not recruiting

APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)

Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

United States, Australia, Brazil, Bulgaria, France, Italy, Japan, Mexico, Netherlands, Taiwan, United Kingdom, Belgium, Czechia, Denmark, New Zealand, Sweden, Korea, Republic of, Argentina, Chile, Hong Kong, Portugal
Alnylam Pharmaceuticals

Active, not recruiting

HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

United States, Poland, Argentina, Australia, Belgium, France, Germany, Japan, Netherlands, Portugal, Spain, Sweden, United Kingdom, Canada, Czechia, Denmark, Hungary, Ireland, Norway, Korea, Republic of, Austria, Croatia, Israel, Latvia, Lithuan... and more
Ionis Pharmaceuticals, Inc.

Completed

Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)

Amyloidosis | Familial Amyloid Polyneuropathy | FAP | TTR | Transthyretin

United States, Spain, Argentina, Brazil, France, Germany, Italy, Portugal, United Kingdom
Ionis Pharmaceuticals, Inc.

Completed

Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy

Amyloidosis | Familial Amyloid Polyneuropathy | FAP | TTR | Transthyretin

New Zealand, United States, Spain, Argentina, Brazil, France, Germany, Italy, Portugal, United Kingdom
Ionis Pharmaceuticals, Inc.

Recruiting

A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

United States, Italy, Portugal, Spain, Taiwan, Sweden, Canada, Brazil, France, New Zealand, Argentina, Cyprus, Australia, Turkey

Clinical Trials on TTR-mediated Amyloidosis

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Luxembourg

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations